Avid­i­ty tops up IPO at $298M; Bris­tol My­ers keeps a Cel­gene dis­cov­ery pact alive

→ The un­der­writ­ers of Avid­i­ty Bio­sciences’ IPO have ex­er­cised their op­tion to pur­chase ad­di­tion­al shares, bring­ing the to­tal amount raised from $259 mil­lion to $298 mil­lion. List­ing un­der the sym­bol $RNA, the biotech con­ju­gates an­ti­sense oligonu­cleotides with hom­ing an­ti­bod­ies to tar­get mus­cle dis­or­ders.

→ Bris­tol My­ers Squibb is keep­ing a Cel­gene part­ner and car­ry­ing over a dis­cov­ery pact fo­cused on deu­biq­ui­ty­lase (DUB) en­zyme in­hibitors. Dundee, Scot­land-based Ubiquigent spe­cial­izes in sup­port­ing drug de­vel­op­ers in­ter­est­ed in pro­tein degra­da­tion through its screen­ing plat­form, a port­fo­lio of ready-to-li­cense com­pounds as well as eval­u­a­tion ser­vices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER